More about

Pituitary Tumor

News
July 27, 2023
3 min read
Save

Genetic aspects of pituitary tumors: A conversation with Márta Korbonits, MD, PhD, DSc

Márta Korbonits, MD, PhD, DSc, FRCP, uncovered a passion for endocrinology from a series of inspirational lectures during her medical training.

News
June 12, 2022
4 min watch
Save

VIDEO: New Cushing’s, acromegaly drug data prominent at ENDO annual meeting

ATLANTA — In this video exclusive, Maria Fleseriu, MD, FACE, reviews the pituitary research presented at the annual meeting of the Endocrine Society in Atlanta.

News
August 24, 2021
2 min read
Save

ACROSTUDY: Pegvisomant safe, effective for long-term use in acromegaly

Real-world data from the long-term ACROSTUDY show the growth hormone receptor agonist pegvisomant is safe and effective, with a low incidence of liver enzyme elevation and no increase in tumor size for most patients with acromegaly.

News
August 10, 2021
3 min read
Save

Experts offer recommendations for management of pituitary tumors

An international panel reached consensus for pre- and postoperative endocrine testing to manage adults undergoing transsphenoidal surgery, including measurement of prolactin and insulin-like growth factor I levels for all pituitary tumors.

News
January 25, 2021
4 min read
Save

Pituitary region tumors comprise ‘significant proportion’ of pediatric brain tumors

Nearly 20% of pediatric brain tumors occur in the pituitary region, and more than two-thirds of pituitary region tumors were present in girls, according to study findings published in Pituitary.

News
May 06, 2020
2 min read
Save

GH therapy plays ‘neutral role’ on recurrence of pituitary tumors

Treatment with recombinant human growth hormone does not increase the risk for nonfunctioning pituitary adenoma or craniopharyngioma among adults with GH deficiency, according to an analysis of retrospective data published in The Journal of Clinical Endocrinology & Metabolism.

News
January 07, 2020
2 min read
Save

Pasireotide reduces pituitary tumor volume in Cushing’s disease

Most adults with persistent or recurrent Cushing’s disease treated with the somatostatin analogue pasireotide experienced a measurable decrease in MRI-detectable pituitary tumor volume at 12 months, according to findings from a post hoc analysis of a randomized controlled trial.

News
November 27, 2019
2 min read
Save

National readmission rate remains at 10% after pituitary surgery

The national 30-day unplanned readmission rate following transsphenoidal surgery for pituitary lesion held at 10.4% between 2010 and 2015, despite a national focus on reducing readmission rates, according to findings from a database analysis published in Pituitary.

News
October 16, 2019
2 min read
Save

Poor quality of life persists after pituitary tumor surgery

Individuals with adult-onset craniopharyngioma reported postoperative quality of life measures that were comparable with those of other primary and secondary brain tumors, despite the benign biology of the condition, according to an analysis of German registry data published in The Journal of Clinical Endocrinology & Metabolism.